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Background: Yin Yang 1 (YY1) is a transcription factor that regulates diverse biological processes and increasing
recognized to have important roles in carcinogenesis. The function and clinical significance of YY1 in gastric
adenocarcinoma (GAC) have not been elucidated.
Methods: In this study, the functional role of YY1 in gastric cancer was investigated by MTT proliferation assays,
monolayer colony formation, cell cycle analysis, signaling pathway analysis, Western blot analysis and in vivo study
through YY1 knockdown or overexpression. Immunohistochemical study with YY1 antibody was performed on tissue
microarray consisting of 247 clinical GAC samples. The clinical correlation and prognosis significance were evaluated.
Results: YY1 expression was up-regulated in gastric cancer cell lines and primary gastric cancers. Knocking down YY1
by siYY1 inhibited cell growth, inducing G1 phase accumulation and apoptosis. Ectopic YY1 expression enhanced cell
proliferation in vitro and in vivo. Knocking down YY1 in gastric cancer cells suppressed proliferation by inhibiting Wnt/
β-catenin pathway, whereas its overexpression exerted oncogenic property by activating Wnt/β-catenin pathway. In
primary GAC samples, YY1 nuclear expression correlated with shorter survival and predicted poor prognosis in early
stage GACs.
Conclusion: Our data demonstrated that YY1 contributes to gastric carcinogenesis in gastric cancer. In early stage
GACs YY1 might serve as a poor prognostic marker and possibly as a potential therapeutic target.
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Gastric adenocarcinoma (GAC) is one of the most com-
mon malignancies in the world, with high rates of inci-
dence in countries such as China, Japan, and South Korea
[1]. Currently, GAC is one of the leading causes of cancer-
related death worldwide, accounting for approximately
740,000 cases of cancer-related death annually [2]. While
various factors such as H. pylori infection, genetic,* Correspondence: kfto@cuhk.edu.hk
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unless otherwise stated.epigenetic and molecular alterations affecting signaling
pathways as well as genetic instability have been impli-
cated in gastric tumorigenesis, the mechanisms of GAC
pathogenesis are still largely unknown [3].
Yin Yang 1 (YY1) is a ubiquitously distributed tran-
scription factor belonging to the Gli-Kruepple class of
Zinc-finger proteins [4]. YY1 has diverse and complex bio-
logical functions and is involved in both repression and
activation of numerous genes that play essential roles in a
multitude of biological processes [5]. For example, YY1
has been shown to positively regulate several oncogenes,
including c-Fos [6], c-Myc [7] and ERBB2 [8,9]. On the
other hand, YY1 has also been found to negatively regulated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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p73 [12] and p53 [13].
YY1 was implicated in the carcinogenesis of a number
of malignancies [14]. For example, by binding to the
Snail 3′ enhancer, YY1 regulates the transcription of
Snail in human melanoma cells [15]. In osteosarcoma,
YY1 appears to be responsible for the tumor cells’ ability
to invade and metastasize [16,17], and overexpression of
YY1 in the primary site of osteosarcoma has shown to
be associated with increased occurrence of metastasis
and poor clinical outcome [18]. By affecting cell cycle
and cellular motility, YY1 is involved in the transform-
ation of non-neoplastic B cells to high grade B cell
lymphomas [19]. In prostate cancer, YY1 physically in-
teracts with androgen receptor (AR), which is required
for the optimal transcriptional activity of AR in promo-
ting the transcription of the prostate-specific antigen
(PSA), a protein enhancing cell migration and metastasis
[20]. YY1 promotes the expression of miR-190, a micro-
RNA that is up-regulated in hepatic and pancreatic
cancers and may play a role in AKT activation thus pro-
motes growth factor-mediated cell survival [21,22].
In contrast, YY1 might serve as a tumor suppressor
gene in several cancer types. In breast cancer, for in-
stance, YY1 positively regulates the expression of breast
cancer-associated gene 1 (BRCA1) [23] and heterochro-
matin protein 1 (HP1) [24]. YY1 also enhances the tumor
suppressor DnaJ-like heat shock protein 40 (HLJ1) expres-
sion in a lung cancer cell model [25,26]. In follicular
lymphoma, YY1 appears to act as a tumor suppressor and
overexpression of YY1 is associated with favorable out-
come with longer survival [27].
The expression and functional role of YY1 in gastric
cancer is still unknown. In the current study, we aimed to
investigate the functional role of YY1 in GAC and to
examine its clinical significance in gastric cancer patients.
Methods
Cell line and cell culture
Ten gastric cancer cell lines (MKN28, KATOIII, MKN45,
SNU16, SNU1, MKN7, MKN1, NCI-N87, AGS and
MGC-803) were obtained from either the American Type
Culture Collection (Rockville, MD) or RIKEN Cell Bank
(Tsukuba, Japan), or received as a gift from Institute Di-
gestive Disease of Prince Wales Hospital. These cell lines
were grown in RPMI 1640 (GIBCO, Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS) (GIBCO,
Grand Island, NY), 100 U/ml penicillin and 10 μg/ml
streptomycin in a humidified atmosphere of 5% CO2
at 37°C.
Patients and clinical GAC samples
The study was approved by Joint Chinese University of
Hong Kong–New Territories East Cluster ClinicalResearch Ethics Committee, Hong Kong (CREC Ref. No.
2009.521) and all participants provided written informed
consent for the collection of samples and subsequent ana-
lysis. A total of 264 GAC samples were retrieved from the
tissue bank of Anatomical and Cellular Pathology, Prince
of Wales Hospital, Hong Kong from 1998 to 2006. The
264 GAC samples were embedded into tissue microarray
blocks. Another 10 pairs of primary tumors and adjacent
non-tumorous tissues were collected intra-operatively
from patients with GAC who had not received radio-
therapy or chemotherapy prior to surgery. These speci-
mens were immediately snap frozen at −80°C for
molecular analysis.
Immunohistochemistry and scoring
Immunohistochemistry was performed according to
methods described previously [28]. Briefly, 4-μm-thick
sections were obtained from formalin-fixed and paraffin-
embedded specimens. After de-waxing in xylene and
graded ethanol, sections were incubated in 3% H2O2 solu-
tion for 25 minutes to block endogenous peroxidase acti-
vities and then subjected to microwaving in EDTA buffer
for antigen retrieval. Next, the tissue sections were incu-
bated with the primary monoclonal YY1 antibodies (1:50,
H-10, sc-7341, Santa Cruz Biotechnology, Dallas, TX)
overnight at 4°C, and chromogen development was per-
formed using the Envision system (DAKO Corporation,
Glostrup, Denmark). The slides were independently
scored by two investigators. The nuclear expression of
YY1 was scored by estimating the proportion of tumor
cells with positive nuclear staining into 4 different groups
(0, none; 1+, <=10%; 2+, 10 to < =25%; 3+, >25%).
RNA extraction and semiquantitative RT-PCR
Total RNA extraction was performed using TRIzol re-
agent (Invitrogen, Grand Island, NY) according to manu-
facturer’s instructions. RNA concentration was measured
by NanoDrop 1000 (Thermo Fisher Scientific, Waltham,
MA). High-Capacity cDNA Reverse Transcription Kits
(Applied Biosystems, Grand Island, NY) were used for
cDNA synthesis. For semiquantitative RT-PCR, 30-cycle
touchdown PCR was applied for YY1 with sense primer
GTCACCATGTGGTCCTCAGA and antisense primer
CTGAGAGGTCAATGCCAGGT. The relative expression
level was normalized with β-actin.
Western blot analysis
Total protein was extracted from gastric cancer cell lines
and paired primary tumors and non-tumorous tissues
using RIPA lysis buffer with proteinase inhibitor. Protein
concentration was measured by the method of Bradford
(Bio-Rad, Hercules, CA). Twenty-microgram of protein
mixed with 2 × SDS loading buffer were loaded on each lane,
separated by 12% SDS-polyacrylamide gel electrophoresis.
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(1:1000, H-10, sc-7341, Santa Cruz Biotechnology, Dallas,
TX). Other antibodies applied included cleaved-PARP
(Asp214) (1:1000, #9541, Cell Signaling, Danvers, MA),
active-β-catenin (1:1000, #05-665, Millipore, Billerica,
MA), β-catenin (1:10000, #610154, BD Transduction La-
boratories, San Jose, CA), CCND1 (1:1000, #2926, Cell
Signaling, Danvers, MA ), c-Myc (1:1000, #9402, Cell Sig-
naling, Danvers, MA), anti-Mouse IgG-HRP (1:30000,
#00049039, Dako, Glostrup, Denmark) and anti-Rabbit
IgG-HRP (1:40000, #00028856, Dako, Glostrup, Denmark).
Functional study assays in vitro
For cell proliferation assays, transfection of YY1
siRNA (SI00051912, QIAGEN, Valencia, CA), siCTNNB1
(SI02662478, QIAGEN, Valencia, CA) and scramble
controls was performed by Lipofectamine 2000 Transfec-
tion Reagent (Invitrogen, Grand Island, NY). For the
transfection of pcDNA3.1+ empty vector control and
YY1, FuGENE HD transfection reagent (Roche, Basel,
Switzerland) was employed. Cell proliferation was assessed
using CellTiter 96 Non-Radioactive Cell Proliferation
Assay (Promega, Madison, WI) according to manufac-
turer’s instructions. For colony formation assays in
monolayer cultures, cells transfected with YY1 siRNA or
scramble control were seeded into 6-well plates and cul-
tured for 8 days. For YY1 overexpression colony formation
assays, the transfected cells were selected by G418
(100 ng/ml) for 2 weeks. Cells were fixed with 70% ethanol
for 15 minutes and stained with 2% crystal violet. Colonies
with more than 50 cells per colony were counted. The ex-
periments were repeated in triplicate wells. For cell cycle
analysis, AGS, MKN28 and NCI-N87 cells were collected
24 hours following transfection in 6-well plates. Before
transfection with siYY1, the cells underwent serum-free
starvation for 12 hours for synchronization. Cells were
harvested using cold PBS and fixed in 70% cold ethanol
overnight at 4°C and treated with 1 ng/ml RNase A for
10 minutes at 37°C. Cellular DNA was stained with
15 ng/ml propidium iodide (PI) for 30 minutes at 37°C
in the dark. The cells then were sorted by FACS Cali-
bur Flow Cytometer (Becton Dickinson, San Diego, CA)
and cell-cycle profiles were determined using the Mo-
dFitLT software (Becton Dickinson, San Diego, CA).
The experiments were repeated twice.
Signaling pathway analysis and validation
Cancer 10-pathway Reporter Luciferase Kit (QIAGEN,
Valencia, CA) was employed to investigate the possible
signaling pathways in which YY1 might be involved in 4
gastric cancer cell lines, AGS, MKN28, NCI-N87 and
MGC-803. These cell lines were transfected with siYY1
and seeded in the Kit plate for luciferase activity detec-
tion. The Wnt/β-catenin signaling pathway was validatedby TOPflash (reporter plasmid containing multiple co-
pies of wild-type Tcf-binding sites) luciferase assays.
In vivo tumorigenicity study
For YY1 knockdown in vivo study, MKN45 cells were
transfected with empty vector (pBABE) and with shYY1.
After puromycin selection, the cells (1 × 106 cells sus-
pended in 0.1 ml PBS) were injected subcutaneously into
the dorsal flank of eight 4-week-old male Balb/c nude
mice (shYY1 on the right side and the negative control
cells on the left). Tumor diameter was measured and
documented every 3 days until the tumor reached
10 mm in diameter. For YY1 overexpression in vivo
study, MKN45 was transfected with empty vector
(pcDNA3.1+) and with YY1. After G418 selection, the
pool with stable YY1 overexpression and their control
counterparts were injected subcutaneously into the dor-
sal flank of eight Balb/c nude mice (YY1 on the right
side and the empty vector control cells on the left).
Tumor diameter was measured and documented every
2 days until the tumors reached 10 mm in diameter. The
mice were sacrificed and xenografts were removed for
further validation. Tumor volume (mm3) was estimated
by measuring the longest and shortest diameter of the
tumor and calculated using the following formula: vol-
ume = (shortest diameter)2 × (longest diameter) × 0.5. All
animal handling and experimental procedures were ap-
proved by the Animal Ethics Committee of the Chinese
University of Hong Kong.
Statistical analysis
The Mann–Whitney U test was used to compare the dif-
ference in biological behavior between siYY1 knockdown
cells and scramble siRNA transfected cells. Correlations
between YY1 nuclear stain and clinicopathologic param-
eters were assessed by the non-parametric Spearman’s
rho rank test. The Kaplan-Meier method was used to es-
timate the survival rates for each variable. The equiva-
lences of the survival curves were tested by log-rank
statistics. For those variables being statistically signifi-
cant found in the univariate survival analysis (p < 0.05),
the Cox proportional hazards model with the likelihood
ratio statistics was employed to further evaluate them
for multivariate survival analysis. All statistical analyses
were carried out using the statistical program SPSS ver-
sion 16.0. A two-tailed p-value of < 0.05 was regarded as
statistically significant.
Results
Up-regulation of YY1 in gastric cancer cell lines and
primary GACs samples
Up-regulation of YY1 protein was detected in 9 gastric
cancer cell lines by Western blot analysis (Figure 1A). In
contrast, the 3 non-neoplastic gastric tissue samples
Figure 1 YY1 expression in gastric cancer cell lines and clinical GAC samples. (A) YY1 protein expression in 9 gastric cancer cell lines and 3
normal gastric tissues. (B) Western blot of YY1 in 10 pairs of gastric tumors (T) and the corresponding non-tumorous mucosa (N). (C) The expression of
YY1 mRNA in 9 gastric cancer cell lines and 5 normal gastric tissues. (D) YY1 mRNA expression in 28 paired primary GACs (N, adjacent non-tumorous
tissue; T, tumor tissue; H, water as negative control).
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regulated YY1 protein expression was observed in 9 out
of 10 primary GACs but not seen in any of the adjacent
non-tumorous gastric tissues (Figure 1B). YY1 mRNA
also showed positive expression in 9 gastric cancer cell
lines, but there was no obvious expression in 5 normal
gastric tissues (Figure 1C). In 28 paired GAC cDNAs, 15
cases showed strong expression of YY1 in tumor tissue
compared with adjacent non-tumorous tissue (Figure 1D).
YY1 knockdown has anti-oncogenic effect in GAC cells
in vitro
YY1 protein was knocked down in AGS, MKN28 and
NCI-N87 cells by siRNAmediated degradation (Figure 2A).
A significantly decreased cellular proliferation was ob-
served in these cell lines when compared with scramble
siRNA groups (p < 0.001, Figure 2B). Monolayer colony
formation assay indicated that YY1 knockdown signifi-
cantly reduced colony formation in these cell lines (p <
0.001, Figure 2C). The transfectants were then analyzed
for cell cycle parameters using flow cytometry. Twenty-
four hours after transfection, accumulation of G1 cells
increased from 52.6% to 55.3% in AGS, from 26.2% to36.0% in MKN28, and from 46.6% to 49.4% in NCI-N87
(Figure 2D). The same trends were observed in a re-
peated set of experiments. Moreover, siYY1 induced late
apoptosis, represented by an increase of cleaved-PARP,
in three gastric cancer cell lines AGS, MKN28 and NCI-
N87 (Figure 2E).
YY1 knockdown suppresses Wnt/β-catenin signaling
pathway and inhibits tumor growth in vivo
By using Cancer 10-pathway Reporter Luciferase Kit, we
found that siYY1 suppressed Wnt/β-catenin signaling path-
way in AGS, MKN28 and MGC-803 cell lines (Figure 3A).
We subsequently used TOPflash luciferase assays to con-
firm that Wnt/β-catenin signaling pathway was indeed
inhibited by siYY1 in AGS, MKN28, NCI-N87 and MGC-
803 cells (Figure 3B). Suppression of Wnt/β-catenin sig-
naling pathway by siYY1 as indicated by decreased active-
β-catenin, CCND1 and c-Myc was observed in siYY1
transfected AGS, MKN28 and NCI-N87 cells (Figure 3C).
The effect of shYY1 expression on in vivo growth of
tumor was also studied. We first selected MKN45 clones
which stably expressed shYY1 and validated the down-
regulated YY1 in shYY1 stable clones by Western blot
Figure 2 YY1 knockdown inhibited proliferation in gastric cancer cell lines. (A) Transfection with YY1 siRNA decreased YY1 protein
expression in AGS, MKN28 and NCI-N87 cells. (B) 5-day MTT assays revealed YY1 siRNA suppressed gastric cancer cell proliferation (**, p < 0.001).
(C) Monolayer colony formation assays suggested transfection with siYY1 reduced monolayer colony formation to 41.1%, 27.8% and 49.7% in
AGS, MKN28 and NCI-N87 cells, respectively (**, p < 0.001). The experiments were done in triplicates. (D) Flow cytometry analysis revealed the
accumulation of cells in G1 phase 24 hours after siYY1 treatment. Representative data from two independent experiments was shown. (E) Western
blot of cleaved-PARP after siYY1 treatment in AGS, MKN28 and NCI-N87 cells.
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Figure 3 YY1 knockdown suppressed Wnt/β-catenin signaling pathway and inhibits tumor growth in vivo. (A) Relative luciferase activity
of Wnt/β-catenin signaling pathway in 4 gastric cancer cell lines after siYY1 treatment. (B) Relative luciferase activity of TOPflash in AGS, MKN28,
NCI-N87 and MGC-803 cells with siYY1 transfection (*, p < 0.05; **, p < 0.001). (C) Western blot of active-β-catenin, total β-catenin, CCND1 and c-Myc
after siYY1 transfection in AGS, MKN28 and NCI-N87 cells. (D1) Western blot of YY1 expression in stable clones of shYY1-MKN45 and the vector control.
(D2) shYY1-MKN45 formed smaller xenograft tumors than pBABE-MKN45 30 days after subcutaneous injection (**, p < 0.001).
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clones were injected into nude mice subcutaneously.
The tumor growth in shYY1 expressing clones was sig-
nificantly decreased compared with the vector control
clones 30 days after injection (p < 0.001, Figure 3D2).
YY1 overexpression enhances tumor growth both in vitro
and in vivo
To further investigate the YY1 functions in gastric can-
cer cells, we overexpressed YY1 into AGS, MKN28 and
NCI-N87 cells. YY1 expression was first evaluated by
Western blot after ectopic expression. Meanwhile active-
β-catenin showed increased level (Figure 4A). YY1 over-
expression increased cell proliferation in these three cell
lines in 5-day MTT assays (p < 0.05, Figure 4B). To con-
firm the proliferation-promoting effect by YY1 through
Wnt/β-catenin signaling pathway, siCTNNB1 (25 nM)
was transfected into the cultured cells to knockdownWnt pathway effector β-catenin. The β-catenin was ef-
fectively knocked down and the same grow suppressive
effect was observed (Figure 4C), indicating that Wnt/
β-catenin signaling pathway plays an important role in
the YY1-induced tumor growth.
We further examined the effect of YY1 on monolayer
colony formation. Gastric cancer cells over-expressing
YY1 formed more and larger colonies (2.4, 2.3 and 1.9
folds in AGS, MKN28 and NCI-N87) in comparison to
vector control groups, (p < 0.001, Figure 4D). The acti-
vated Wnt/β-catenin signaling pathway together with
upregulation of its downstream effectors CCND1 and
c-Myc were observed in YY1-MKN45 stable clones
(Figure 4E1). The YY1-MKN45 stable clones were
injected subcutaneously into the dorsal flank of 8 nude
mice. Twenty days later, YY1 over-expressing clones
formed larger xenografts than the control clones (p <
0.001, Figure 4E2).
Figure 4 (See legend on next page.)
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Figure 4 YY1 ectopic expression enhanced tumor growth both in vitro and in vivo. (A) Western blot of YY1, active-β-catenin and total β-catenin
after YY1 exogenous overexpression in AGS, MKN28 and NCI-N87 cell lines. (B) 5-day MTT assays revealed YY1 enhanced gastric cancer cell proliferation
(*, p < 0.05). (C) Upper: Western blot of active-β-catenin and total β-catenin under siCTNNB1 treatment. Lower: siCTNNB1 inhibits GAC cell proliferation
(**, p < 0.001). (D) YY1 enhanced monolayer colony formation to 2.4, 2.3 and 1.9 folds in AGS, MKN28 and NCI-N87 cells, respectively, compared with
vector controls (**, p < 0.001). The experiments were done in triplicates. (E1) YY1 ectopic expression activated Wnt/β-catenin signaling pathway in
MKN45 cells by consecutively activating active-β-catenin, CCND1 and c-Myc. (E2) YY1-MKN45 formed bigger xenograft tumors than pcDNA3.1-MKN45
20 days after injection (**, p < 0.001).
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time in patients with early stage GACs
YY1 was predominantly expressed in the nuclei of tumor
cells (Figure 5A; left, case with negative YY1 expression;
right, case with strong YY1 expression). Of the 247 GAC
samples, 98 cases (39.7%) had a YY1 nuclear score 0, 3
cases (1.2%) had a score 1+, 5 cases (2%) had a score of
2+, and 141 cases (57.1%) had a score of 3+. In total,
101 of 247 samples (40.9%) of gastric cancer cases had
negative/weak (0 to 1+) YY1 expression, while 146 of
247 samples (59.1%) had strong YY1 expression (2+ to 3+,
Additional file 1: Figure S1). No survival difference wasFigure 5 YY1 nuclear expression correlated with poor survival in earl
immunohistochemistry in primary GACs. Left, negative/low expression case
insertion × 400). (B) YY1 nuclear expression predicted poor prognosis in ea
expression did not associate with disease specific survival in advanced stagobserved between YY1 negative/weak and strong expres-
sion by univariate analysis (p = 0.341).
We further investigated the clinicopathologic correl-
ation of YY1 by stratifying the patients into early stage
(stage I and II, n = 88) and advanced stage (stage III and
IV, n = 159). Table 1 summarized the correlation of YY1
with clinicopathologic parameters in early stage and ad-
vanced stage patients. In early stage patients, YY1 ex-
pression correlated with diffuse type gastric cancer (p =
0.031). Univariate analysis (Table 2) indicated that YY1
strong expression in early stage GACs associated with
poor disease specific survival (p = 0.045, Figure 5B).y stage gastric cancers. (A) Representative figures of YY1
; right, positive expression case (original magnification × 100,
rly stage GAC patients (stage I and II, p = 0.045). (C) YY1 nuclear
e GACs (stage III and IV, p = 0.958).
Table 1 Correlation of YY1 nuclear expression with clinicopathologic features (significant p-value in bold and italic format)
Early stage cases
(stage I & II, n = 88)
Advanced stage cases
(stage III & IV, n = 159)
YY1 nuclear expression YY1 nuclear expression
Negative/weak Strong p-value Negative/weak Strong p-value
Number (%) Number (%) Number (%) Number (%)
Sex M 12 (20.3) 47 (79.7) 0.969 56 (52.3) 51 (47.7) 0.961
F 6 (20.7) 23 (79.3) 27 (51.9) 25 (48.1)
Age <=60 6 (20.7) 23 (79.3) 0.969 39 (61.9) 24 (38.1) 0.053
>60 12 (20.3) 47 (79.7) 44 (45.8) 52 (54.2)
Type Intestinal 17 (26.2) 48 (73.8) 0.031 47 (61.8) 29 (38.2) 0.020
Diffuse 1 (4.5) 21 (95.5) 36 (43.4) 47 (56.6)
Grade 1 2 (28.6) 5 (79.7) 0.866 1 (100.0) 0 (0.0) 0.033
2 8 (20.0) 32 (80.0) 38 (64.4) 21 (35.6)
3 8 (20.0) 32 (80.0) 44 (44.4) 55 (55.6)
Stage (T) 1 7 (21.2) 26 (78.8) 0.909 1 (50.0) 1 (50.0) 0.971
2 10 (21.3) 37 (78.7) 13 (52.0) 12 (48.0)
3 1 (14.3) 6 (85.7) 65 (52.8) 58 (47.2)
4 4 (44.4) 5 (55.6)
Stage (N) 0 13 (23.6) 42 (76.4) 0.623 1 (50.0) 1 (50.0) 0.841
1 5 (16.1) 26 (83.9) 17 (53.1) 15 (46.9)
2 0 (0.0) 1 (100.0) 36 (48.6) 38 (51.4)
3 29 (56.9) 22 (43.1)
Stage (M) 0 18 (20.5) 70 (79.5) 64 (52.0) 59 (48.0) 0.937
1 19 (52.8) 17 (47.2)
Lymph Node 0 13 (23.6) 42 (76.4) 0.374 1 (50.0) 1 (50.0) 0.950
1 5 (15.6) 27 (84.4) 82 (52.2) 75 (47.8)
H. pylori Absence 7 (18.4) 31 (81.6) 0.743 36 (47.4) 40 (52.6) 0.417
Presence 10 (21.3) 37 (78.7) 41 (53.9) 35 (46.1)
Table 2 Univariate and multivariate Cox regression
analysis of clinicopathologic factors in patients with
gastric adenocarcinoma (significant p-value in bold and
italic format)
Early stage cases
(stage I & II, n = 88)
Advanced stage cases
(stage III & IV, n = 159)
Univariate Multivariate Univariate Multivariate
Sex 0.900 0.318
Age 0.120 0.006 0.003
Type 0.342 0.654
Grade 0.594 0.747
Stage (T) 0.974 0.088
Stage (N) 0.656 0.002 <0.001
Stage (M) <0.001 <0.001
H. pylori 0.003 0.007 0.611
YY1 0.045 0.970 0.958
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survival (p = 0.003). By multivariate Cox proportional
hazards regression analysis (Table 2), only H. pylori in-
fection was independently associated with disease spe-
cific survival (p = 0.007).
In advanced stage GACs (Table 1), YY1 nuclear expres-
sion correlated with histology with diffuse component
(p = 0.020), higher tumor grade (p = 0.033). However, YY1
expression could not predict survival (Figure 5C, p =
0.958) by univariate analysis. Old age (age > 60, p = 0.006),
advanced N stage (p = 0.002) and advanced M stage (p <
0.001) also predicted poor prognosis. By multivariate Cox
proportional hazards regression analysis, age, N stage and
M stage remained the independent prognostic factors for
patients with advanced gastric cancer.
Discussion
YY1 serves either as a tumor suppressor gene or onco-
gene depending on the types of tumors it is expressed in
[23,29-33]. The choice of its function and consequently
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tors such as cell context, oncogenic stimulation or the
regulation of its upstream pathways. As a transcription
factor, YY1 binds the promoter of associated oncogenes
and exert its oncogenic property [34]. In prostate cancer,
YY1 has two binding sites within the prostate stem cell
antigen (PSCA) promoter facilitating development of
malignant human prostate cancer [30]. YY1 also re-
portedly activates the expression of human epidermal
growth factor receptor 2 (ERBB2) [8,9], which is overex-
pressed in approximately 30% of breast cancers and cor-
relates with poor prognosis. YY1 induces expression of
cyclooxygenase-2 (COX-2), which is overexpressed in
40% of human invasive breast cancers and mediates
bone metastasis [35]. In Burkitt lymphoma, YY1 binds
to this HS3 enhancer and recruits CBP to this region,
which increases the histone acetylation of the c-Myc pro-
moter and activates c-Myc gene expression [36]. YY1
forms an active complex with hypoxia inducible factor
(HIF) 1α to activate vascular endothelial growth factor
(VEGF) gene expression [37,38]. In gastric cancer, we pro-
vide the first evidence that YY1 also plays an oncogenic
role. This was indicated by YY1 overexpression enhanced
cell proliferation, monolayer colony formation and xeno-
graft growth whereas YY1 knockdown inhibited gastric
cancer cell proliferation both in vitro and in vivo.
The current study also suggested that YY1 affected
Wnt signaling cascades in gastric cancer cells. By using
Cancer 10-pathway Reporter Luciferase Assay, we iden-
tified that siYY1 inhibited Wnt/β-catenin signaling path-
way in gastric cancer cell lines. The finding was further
validated by the TOPflash luciferase assays. Suppression
of Wnt/β-catenin pathway by siYY1, as evidenced by de-
crease active-β-catenin, CCND1 and c-Myc level had
been demonstrated. On the contrary, YY1 overexpres-
sion promotes Wnt/β-catenin pathway and up-regulates
its targets. These data were in keeping with a recent
finding that YY1 activates Wnt signaling pathway
through activating β-catenin in colon cancer [39]. Using
microarray analysis, Zhang et al. found that YY1 regu-
lated the expression of a number of Wnt-associate genes.
It is plausible to speculate that YY1 might promote the
Wnt signaling pathway by suppressing Wnt antagonists/
inhibitors, i.e. CSNK1A1, CTNNBIP1, SFRP1 and the
deletion variant of LEF-1, and up-regulate Wnt initiators,
i.e. CTNNB1, FZD4, Wnt1 and Wnt3a. Our data clearly
indicated that YY1 acted to promote Wnt/β-catenin sig-
naling in gastric carcinogenesis.
To determine the clinical relevance of YY1 in primary
GACs, we examined the protein expression of YY1 in
247 clinical gastric cancer samples. The overexpression
of YY1 was not correlated with TNM staging, this result
was partly concordant with previous reports that there
were no difference for the YY1 expression betweenprimary tumor and metastatic samples [40]. Neverthe-
less, expression of YY1 associated with diffuse type hist-
ology both in early-stage and advanced-stage GACs,
suggesting that YY1 might be involved in the occurrence
and development of diffuse type GACs. Comparing with
intestinal type GACs, diffuse type GACs are less related
to atrophy or intestinal metaplasia, occur more often in
younger patients and are associated with a poorer prog-
nosis. Our findings supported that YY1 overexpression
is involved in the carcinogenesis diffuse type GACs. In
early stage (stage I and II) GACs, YY1 nuclear expres-
sion correlated with shorter survival and predicts poorer
prognosis. This result was concordant with the clinical
significance of YY1 in colon cancer [39].
Conclusion
In conclusion, we provided both in vitro and in vivo evi-
dence that YY1 contributes to gastric tumorigenesis
through promoting cell survival in GAC cells. Functional
studies demonstrated that downregulation of YY1 ex-
pression by siYY1 quenched its oncogenic properties by
inhibiting cell growth, inducing G1 phase accumulation
and apoptosis. YY1 overexpression enhanced cell proli-
feration by activating the Wnt/β-catenin signaling path-
way. YY1 nuclear expression correlated with poor
prognosis in patients with early stage GAC, suggesting
that YY1 might potentially serve as a prognostic bio-
marker and a therapeutic target in gastric cancer.
Additional file
Additional file 1: Figure S1. Representative figures of YY1
immunohistochemistry in 25 primary GACs with strong YY1 expression (2+
or 3+, original magnification × 100, insertion × 400). The up-regulated
expression of YY1 mainly localized in the nuclei of the cancer cells.
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